Drug class profile · refreshed daily from federal data

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

9 molecules in this class, $52.5M combined CY2024 Part D spend across 265K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 9tracked in Part D
CY24 Part D spend: $52.5Mcombined across class
Total Rx claims: 265K62K unique beneficiaries
Generic mfrs (active): 30across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Entecavir

Brand: BARACLUDE · 210K Part D claims (CY24) · 51K beneficiaries · First FDA approval: 2005-03-29

8 generic mfrs 8 plans require PA

Low NADAC$0.212

→

Avg plan cost$2.36

Part D spend $44.1M 11× spread, current vs floor

Class share

84%

of class CY24 spend

View profile →

Lamivudine

Brand: EPIVIR · 55K Part D claims (CY24) · 11K beneficiaries · First FDA approval: 2010-10-04

10 generic mfrs 1 plans require PA

Low NADAC$0.218

→

Avg plan cost$1.26

Part D spend $8.4M 6× spread, current vs floor

Class share

16%

of class CY24 spend

View profile →

Abacavir , Lamivudine and Zidovudine

Brand: ABACAVIR, LAMIVUDINE AND ZIDOVUDINE · — Part D claims (CY24) · First FDA approval: 2013-12-17

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Abacavir Sulfate, Dolutegravir Sodium, Lamivudine

Brand: Triumeq · — Part D claims (CY24) · First FDA approval: 2014-08-22

Brand-only (no generics) 0 plans require PA

Low NADAC$130.10

→

Avg plan cost$130.10

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Abacavir and Lamivudine

— Part D claims (CY24) · First FDA approval: 2017-03-28

5 generic mfrs 0 plans require PA

Low NADAC$1.45

→

Avg plan cost$1.45

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Dolutegravir and Lamivudine

Brand: Dovato · — Part D claims (CY24) · First FDA approval: 2019-04-08

Brand-only (no generics) 0 plans require PA

Low NADAC$105.26

→

Avg plan cost$105.26

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Lamivudine Oral

Brand: lamivudine · — Part D claims (CY24) · First FDA approval: 2014-10-31

Brand-only (no generics)

Low NADAC$0.218

→

Avg plan cost$0.218

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Lamivudine and Tenofovir Disoproxil

Brand: CIMDUO · — Part D claims (CY24) · First FDA approval: 2018-06-25

Brand-only (no generics) 0 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lamivudine and Zidovudine

Brand: COMBIVIR · — Part D claims (CY24) · First FDA approval: 2010-10-19

7 generic mfrs 0 plans require PA

Low NADAC$0.692

→

Avg plan cost$0.692

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.